Clinical Trials Logo

Clinical Trial Summary

Autism Spectrum Disorder (ASD) is a broad spectrum neurodevelopmental disease. Some individuals with ADS by high cognitive functions are diagnosed with High Functioning Autism (HFA). Learning difficulties and memory problems are detected in children with ASD. In some studies, it has been shown that NEURL1 gene increases learning and memory and RGS14 gene is suppressed them. We aimed to evaluate the differences between the expression levels of these genes between ASD, HFA and healthy controls and the role of these genes in the pathogenesis of ASD. Patients with ASD (N=20) and HFA (N=20), and healthy controls(N=20) compatible with patient ages were included in this study. Expression of NEURL-1 and RGS14 genes was evaluated by quantitative Real Time PCR (qRT-PCR).


Clinical Trial Description

Autism Spectrum Disorders (ASD) is a complex and neuro-developmental disease starting in the early stages of life and is characterized by cognitive and behavioral disorders (Ansel et al., 2008). In addition, the definition of High Functioning Autism (HFA) is used for the individuals who are diagnosed with ASD with an Intelligence Quotient (IQ) of 70 and above with no mental disabilities (Alvares et al., 2020). It is considered that the etiology of ASD stems from genetic, epigenetic and environmental factors; however, it has not yet been definitively clarified(Ito et al., 2017). It was shown in previous studies that individuals who are diagnosed with ASD have learning disabilities (Sullivan et al., 2019) and disorders in cognitive episodic memory, future planning, visual working memory (Goh and Peterson 2012). In some studies, it has been shown that NEURL1 gene increases learning and memory and RGS14 gene is suppressed them (Pavlopoulos et al., 2011; Lee et al., 2010). Considering this information, we aimed to evaluate the differences between the expression levels of these genes between ASD, HFA and healthy controls and the role of these genes in the pathogenesis of ASD. Method: Patients with ASD (n=20) and HFA (n=20), and healthy controls (n=20) compatible with patient ages were included in this study. Clinical evaluations of the patients were made and classification was made in accordance with DSM-IV diagnostic criteria. For RNA isolation, 2 ml of peripheral blood was taken from each subjects. RNA isolation was made in line with the recommended protocol by using the High Pure RNA Isolation Kit (Roche Diagnostic, Version 12, Germany) from the blood samples taken from the groups. The quality and quantity of the RNA was measured with nanodrop (Nanodrop 2000/Thermo Scientific, USA). Analyses were made in the RNAs by using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, GmbH, Mannheim). Since the amount of the target genes is less in the blood, pre-amplification was performed by applying Realtime Ready Assays (NEURL1, RGS14, ACTB genes primary and probes) and Multiplex PCR before Real Time PCR. The expression of the NEURL1 and RGS14 genes were determined with the Semiquantitative Real-Time PCR Method by using the hybrid probe. The LightCycler®480 Real Time Ready Assay Master Probe Kit (Roche Diagnostics, GmbH, Mannheim) was used, and the analysis was made in Light Cycler in the study. The incubation was made with the PCR device program for 10 minutes at 95oC for 45 cycles, for 10 sec at 95oC, and for 60 sec at 60oC. The Ct values were obtained from the Light Cycler 480 Software Program, and both genes were analyzed separately. The 2-ΔΔCT method was applied for the relative quantification of the samples that were normalized with ACTB. Statisticaly: The fitness of the data to normal distribution was evaluated with Histogram, q-q graphics, and Shapiro-Wilk Test. Variance homogeneity was evaluated with the Levene Test. Inter-group comparisons were evaluated with the Pearson's Chi-Square analysis and Fisher's Exact Chi-Square Test for qualitative variables, and with Mann-Whitney U-Test, Kruskal-Wallis H-Test, and One-Way Variance Analysis for quantitative variables. Spearman's test was used for correlation analysis. The data were expressed as mean and standard deviation, or median with 25 and 75 percentages. The analysis of the data was made at R 3.1.1 (www.r-project.org). The P<0.05 level was taken as significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04865198
Study type Observational
Source TC Erciyes University
Contact
Status Completed
Phase
Start date January 10, 2013
Completion date August 30, 2014

See also
  Status Clinical Trial Phase
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1
Completed NCT04052711 - A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design Phase 1
Terminated NCT00001844 - Study of New Magnetic Resonance Methods
Completed NCT04319926 - Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects Phase 1
Completed NCT03160261 - Effect of Exenatide on Cortisol Secretion Phase 4
Completed NCT03662100 - A Study of Two Formulations of LY3074828 in Healthy Participants Phase 1
Recruiting NCT02875301 - Investigating Gains in Neurocognition in an Intervention Trial of Exercise Phase 3
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT03670082 - Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State Phase 1
Completed NCT03656952 - A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers Phase 1
Completed NCT03056846 - Probiotics on Stress-associated Gastrointestinal Function in University Students N/A
Completed NCT03203824 - The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals N/A